SG11201909018VA - Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide - Google Patents

Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Info

Publication number
SG11201909018VA
SG11201909018VA SG11201909018VA SG11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA SG 11201909018V A SG11201909018V A SG 11201909018VA
Authority
SG
Singapore
Prior art keywords
methyl
international
princeton
route
new jersey
Prior art date
Application number
Other languages
English (en)
Inventor
Yanlei Zhang
Michael A Galella
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201909018VA publication Critical patent/SG11201909018VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11201909018V 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide SG11201909018VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478789P 2017-03-30 2017-03-30
PCT/US2018/025114 WO2018183656A1 (en) 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
SG11201909018VA true SG11201909018VA (en) 2019-10-30

Family

ID=62002470

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201909018V SG11201909018VA (en) 2017-03-30 2018-03-29 Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
SG11201908947Q SG11201908947QA (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201908947Q SG11201908947QA (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Country Status (23)

Country Link
US (6) US10899745B2 (cg-RX-API-DMAC10.html)
EP (4) EP4296258A3 (cg-RX-API-DMAC10.html)
JP (6) JP7113023B2 (cg-RX-API-DMAC10.html)
KR (4) KR102642407B1 (cg-RX-API-DMAC10.html)
CN (4) CN116354939A (cg-RX-API-DMAC10.html)
AU (3) AU2018244451B2 (cg-RX-API-DMAC10.html)
CA (2) CA3058209A1 (cg-RX-API-DMAC10.html)
CY (1) CY1124194T1 (cg-RX-API-DMAC10.html)
DK (1) DK3601268T3 (cg-RX-API-DMAC10.html)
EA (2) EA201992308A1 (cg-RX-API-DMAC10.html)
ES (2) ES2864450T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20210764T1 (cg-RX-API-DMAC10.html)
HU (1) HUE054886T2 (cg-RX-API-DMAC10.html)
IL (3) IL305615A (cg-RX-API-DMAC10.html)
LT (1) LT3601268T (cg-RX-API-DMAC10.html)
MX (4) MX2019011231A (cg-RX-API-DMAC10.html)
PL (1) PL3601268T3 (cg-RX-API-DMAC10.html)
PT (1) PT3601268T (cg-RX-API-DMAC10.html)
RS (1) RS61816B1 (cg-RX-API-DMAC10.html)
SG (2) SG11201909018VA (cg-RX-API-DMAC10.html)
SI (1) SI3601268T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202100239T1 (cg-RX-API-DMAC10.html)
WO (2) WO2018183656A1 (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
LT3601268T (lt) * 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
CN118994118A (zh) * 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
KR102943760B1 (ko) * 2019-01-28 2026-03-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
IL291452B1 (en) 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
US12606556B2 (en) 2020-02-26 2026-04-21 Beone Medicines I Gmbh TYK-2 inhibitor
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
US20240043435A1 (en) 2020-06-22 2024-02-08 Beigene, Ltd. Tyk-2 inhibitor
CN115667246B (zh) * 2020-07-24 2024-08-23 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
US20240325388A1 (en) 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
CN116615200B (zh) * 2020-10-20 2025-04-29 杭州领业医药科技有限公司 哒嗪衍生物的晶型
AU2022214313A1 (en) 2021-01-29 2023-08-17 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
JP2024529763A (ja) * 2021-08-20 2024-08-08 ブリストル-マイヤーズ スクイブ カンパニー 6-(シクロプロパンカルボキサミド)-4-((2-メトキシ-3-(1-メチル-1h-1,2,4-トリアゾール-3-イル)フェニル)アミノ)-n-(メチル-d3)ピリダジン-3-カルボキサミドの結晶体
KR20240065283A (ko) * 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
JP2024539703A (ja) 2021-10-28 2024-10-29 ブリストル-マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
US20260159504A1 (en) 2021-12-01 2026-06-11 Assia Chemical Industries Ltd. Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
US12222104B2 (en) * 2022-03-21 2025-02-11 General Electric Company Turbine engine combustor and combustor liner
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法
WO2024017150A1 (zh) * 2022-07-18 2024-01-25 苏州鹏旭医药科技有限公司 一种氘可来昔替尼的合成方法
CN117447411B (zh) * 2022-07-18 2025-12-23 苏州鹏旭医药科技有限公司 一种杂环药物中间体的合成方法
CN120187715A (zh) * 2022-10-28 2025-06-20 浙江华海药业股份有限公司 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途
EP4713315A1 (en) * 2023-05-15 2026-03-25 Alivus Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
EP4538259A1 (en) 2023-10-09 2025-04-16 Farmhispania Group, S.L. Processes for the preparation of deucravacitinib
WO2025131031A1 (zh) 2023-12-22 2025-06-26 上海奥博生物医药股份有限公司 一种TyK2抑制剂及其中间体的制备方法
WO2025173029A1 (en) * 2024-02-14 2025-08-21 Natco Pharma Limited An improved process for the preparation of deucravacitinib
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025259267A1 (en) 2024-06-11 2025-12-18 Vector Vitale Ip Llc Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements
ES3059443A1 (es) * 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023649B2 (ja) 1976-09-08 1985-06-08 東ソー株式会社 臭化水素酸による臭化メチルの製造方法
JPS5455501A (en) 1977-10-05 1979-05-02 Toyo Soda Mfg Co Ltd Continuous preparation of methyl bromide
US4254061A (en) * 1979-09-11 1981-03-03 E. I. Du Pont De Nemours And Company Preparation of monomethylamine
EP1184376B1 (en) 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
ES2394522T3 (es) * 2005-09-29 2013-02-01 Basf Se Cuerpo moldeado que contiene un silicato de aluminio y un óxido de aluminio y procedimiento para la producción continuada de metilaminas
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
CN102573478B (zh) * 2009-10-12 2015-12-16 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
US8748666B2 (en) * 2010-03-18 2014-06-10 Suzhou Zelgen Biopharmaceutical Co., Ltd. Preparation methods of methyl-D3-amine and salts thereof
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
CN104125947A (zh) 2011-12-21 2014-10-29 生物区欧洲有限公司 杂环脲化合物
KR20140108594A (ko) * 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
WO2013171643A1 (en) 2012-05-14 2013-11-21 Piramal Enterprises Limited An improved process for preparation of irbesartan
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
LT3601268T (lt) * 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
CN118994118A (zh) * 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
RS66346B1 (sr) * 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
AU2022214313A1 (en) * 2021-01-29 2023-08-17 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Also Published As

Publication number Publication date
US20210107897A1 (en) 2021-04-15
RS61816B1 (sr) 2021-06-30
MX2019011092A (es) 2020-01-20
EP4296258A2 (en) 2023-12-27
EP3601270A1 (en) 2020-02-05
JP2026067880A (ja) 2026-04-21
PT3601268T (pt) 2021-04-13
US10899745B2 (en) 2021-01-26
CN110475774A (zh) 2019-11-19
KR102720054B1 (ko) 2024-10-22
AU2018244451A1 (en) 2019-11-21
JP7476370B2 (ja) 2024-04-30
MX2022010496A (es) 2022-09-21
JP7457758B2 (ja) 2024-03-28
MX2019011231A (es) 2019-11-18
EA201992300A1 (ru) 2020-02-20
JP2022166011A (ja) 2022-11-01
KR102857398B1 (ko) 2025-09-08
MX392693B (es) 2025-03-12
SG11201908947QA (en) 2019-10-30
CN110475774B (zh) 2023-06-02
PL3601268T3 (pl) 2021-07-05
WO2018183656A1 (en) 2018-10-04
KR20190133725A (ko) 2019-12-03
EP3882237B1 (en) 2023-12-20
LT3601268T (lt) 2021-05-25
CY1124194T1 (el) 2022-05-27
JP7260481B2 (ja) 2023-04-18
BR112019020169A2 (pt) 2020-04-22
MX2022010495A (es) 2022-09-21
CN116354939A (zh) 2023-06-30
BR112019020163A2 (pt) 2020-04-22
AU2018244916A1 (en) 2019-11-21
HUE054886T2 (hu) 2021-10-28
SMT202100239T1 (it) 2021-05-07
KR20190133726A (ko) 2019-12-03
US20230271946A1 (en) 2023-08-31
IL269586B (en) 2022-08-01
JP7113023B2 (ja) 2022-08-04
AU2018244916B2 (en) 2021-11-18
KR20240154690A (ko) 2024-10-25
JP2024037836A (ja) 2024-03-19
CA3058177A1 (en) 2018-10-04
KR102642407B1 (ko) 2024-02-28
EP3882237A2 (en) 2021-09-22
ES2970229T3 (es) 2024-05-27
IL305615A (en) 2023-11-01
HRP20210764T1 (hr) 2021-07-09
JP2020512370A (ja) 2020-04-23
KR20250080914A (ko) 2025-06-05
US20260167628A1 (en) 2026-06-18
DK3601268T3 (da) 2021-05-03
US12565487B2 (en) 2026-03-03
EP3601268A1 (en) 2020-02-05
CA3058209A1 (en) 2018-10-04
US20210371404A1 (en) 2021-12-02
US12545665B2 (en) 2026-02-10
WO2018183649A1 (en) 2018-10-04
US11649226B2 (en) 2023-05-16
IL269594B1 (en) 2023-10-01
IL269594A (en) 2019-11-28
AU2021261839B2 (en) 2023-07-20
CN110914260A (zh) 2020-03-24
AU2021261839A1 (en) 2021-12-02
EP4296258A3 (en) 2024-03-20
US20200239449A1 (en) 2020-07-30
ES2864450T3 (es) 2021-10-13
SI3601268T1 (sl) 2021-07-30
JP7837938B2 (ja) 2026-03-31
CN116813561B (zh) 2026-06-16
CN116813561A (zh) 2023-09-29
IL269594B2 (en) 2024-02-01
AU2018244451B2 (en) 2022-03-10
EP3601268B1 (en) 2021-03-17
EP3882237A3 (en) 2021-11-03
JP2023052683A (ja) 2023-04-11
US20200109134A1 (en) 2020-04-09
IL269586A (en) 2019-11-28
JP2020512380A (ja) 2020-04-23
EA201992308A1 (ru) 2020-02-13

Similar Documents

Publication Publication Date Title
SG11201908947QA (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201907209QA (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201808878UA (en) Heterocyclic compounds as ret kinase inhibitors
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201810837QA (en) Biarylmethyl heterocycles
SG11201808163WA (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide